SVRA Savara Inc

Price (delayed)

$5

Market cap

$1.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.58

Enterprise value

$1.02B

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 45
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary ...

Highlights
Savara's equity has increased by 19% YoY but it has decreased by 18% from the previous quarter
SVRA's net income is down by 26% YoY and by 8% from the previous quarter
SVRA's quick ratio is down by 25% from the previous quarter and by 9% YoY

Key stats

What are the main financial stats of SVRA

SVRA stock price

How has the Savara stock price performed over time
Intraday
-5.66%
1 week
-2.53%
1 month
-10.55%
1 year
43.68%
YTD
-17.08%
QTD
-18.83%

Financial performance

How have Savara's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$143.63M
Net income
-$139.31M
Gross margin
N/A
Net margin
N/A
SVRA's net income is down by 26% YoY and by 8% from the previous quarter
Savara's operating income has decreased by 22% YoY and by 7% from the previous quarter

Price vs fundamentals

How does SVRA's price correlate with its fundamentals

Growth

What is Savara's growth rate over time

Valuation

What is Savara stock price valuation
P/E
N/A
P/B
7.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 16% YoY and by 3.6% QoQ
The stock's price to book (P/B) is 104% more than its 5-year quarterly average of 3.7 and 10% more than its last 4 quarters average of 6.9
Savara's equity has increased by 19% YoY but it has decreased by 18% from the previous quarter

Efficiency

How efficient is Savara business performance
Savara's ROIC has decreased by 37% YoY and by 8% from the previous quarter
SVRA's ROE is down by 31% YoY and by 3.6% from the previous quarter
SVRA's return on assets is down by 26% year-on-year and by 3.9% since the previous quarter

Dividends

What is SVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SVRA.

Financial health

How did Savara financials performed over time
SVRA's current ratio is down by 25% since the previous quarter and by 9% year-on-year
SVRA's quick ratio is down by 25% from the previous quarter and by 9% YoY
The debt is 79% smaller than the equity
The debt to equity has grown by 24% from the previous quarter but it has contracted by 16% YoY
Savara's equity has increased by 19% YoY but it has decreased by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.